Strides Focuses On Emerging Markets After ‘Challenging’ Q1
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Strides Arcolab, rated by local analysts as one of the top small-cap pharma picks, says it is betting on emerging markets, ramping up research and development and scouting for new acquisitions to drive earnings following a “challenging” fiscal first quarter.